Via Scientific, a Boston, MA-based developer of a platform enabling pharmaceutical companies, bio-techs and academic researchers to discover novel biological insights, raised $5M in Seed funding.
The round was led by G20 Ventures and Innospark Ventures. The syndicate also included Life Science and AI Angel investors including Melissa J. Moore, former CSO of Moderna, Rob Hickey, Former EVP at DataRobot, and Janet Kosloff, Founder, and former CEO of InCrowd, Inc.
The company intends to use the funds to further accelerate its go-to-market activities, extend its existing library of hundreds of bioinformatic processes, pipelines, and AI models, and to expand its technology and scientific teams.
Led by CEO Jim Crowley, and CTO Alper Kucukural, Via Scientific is the developer of Via Foundry, the multi-omics platform that enables pharmaceutical companies, bio-techs and academic researchers to discover novel and reproducible biological insights. Originally developed in the Bioinformatics Core at the University of Massachusetts Chan Medical School, Via Scientific’s multi-omics platform enables researchers to study life in a concerted way, leveraging AI to analyze large scale, complex, and dynamic biological data to find novel associations between biological entities, pinpoint relevant biomarkers and pathways, and to identify markers of disease and physiology.
FinSMEs
09/01/2024